Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis

The aim of this study is to determine whether intravenous delivery of allogeneic CD34+ peripheral blood-derived hematopoietic stem cells (PB-HSCs) is effective in the treatment of patients with primary myelofibrosis, when treated following a reduced intensity conditioning regimen.